Afficher la notice abrégée

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study

dc.rights.licenseopenen_US
dc.contributor.authorLEBRETON, C.
dc.contributor.authorCANTAREL, C.
dc.contributor.authorTOULZA, E.
dc.contributor.authorDESGRIPPES, R.
dc.contributor.authorBOZEC, L.
dc.contributor.authorSAADA, E.
dc.contributor.authorDUCOULOMBIER, A.
dc.contributor.authorTARDY, M.
dc.contributor.authorPAILLAUD, E.
dc.contributor.authorLALET, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorITALIANO, A.
dc.date.accessioned2021-03-18T08:33:57Z
dc.date.available2021-03-18T08:33:57Z
dc.date.issued2020-09-22
dc.identifier.issn1879-4068en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26716
dc.description.abstractEnMost of the safety data of tyrosine and serine/threonine kinase inhibitors (TKIs) approved for cancer treatment are extrapolated from larger trials in which older patients generally accounted for a small fraction of the participants. The Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer study (PreToxE)PreToxE study aims to describe the incidence and prognostic factors of clinically meaningful toxicities of TKI in patients with cancer aged over 70 years. The primary endpoint was incidence of severe toxicity, defined as treatment-related death, persistent or significant disability/incapacity, hospitalization or the discontinuation of TKI treatment for more than three weeks. Our results indicate that despite frequent upfront dose reduction, clinically meaningful toxicities occurred in approximately 40% of older patients treated with TKIs. The use of at least three concomitant medications is an independent predictor of clinically meaningful toxicities.
dc.language.isoENen_US
dc.title.enIncidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study
dc.title.alternativeJ Geriatr Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jgo.2020.09.020en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32978101en_US
bordeaux.journalJournal of Geriatric Oncologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03172891
hal.version1
hal.date.transferred2021-03-18T08:34:01Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Geriatric%20Oncology&rft.date=2020-09-22&rft.eissn=1879-4068&rft.issn=1879-4068&rft.au=LEBRETON,%20C.&CANTAREL,%20C.&TOULZA,%20E.&DESGRIPPES,%20R.&BOZEC,%20L.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée